Analyzing Rani Therapeutics (RANI) and Its Peers

Rani Therapeutics (NASDAQ:RANI) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Rani Therapeutics to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Rani Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1	0	4	0	2.60
Rani Therapeutics Competitors	9839	15124	45439	1588	2.54

Rani Therapeutics currently has a consensus target price of $8.33, suggesting a potential upside of 1,424.02%. As a group, “Biotechnology” companies have a potential upside of 102.83%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Rani Therapeutics is more favorable than its competitors.

Valuation and Earnings

This table compares Rani Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rani Therapeutics	$4.88 million	-$29.67 million	-2.03
Rani Therapeutics Competitors	$734.33 million	$13.94 million	-15.16

Rani Therapeutics’ competitors have higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Rani Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Rani Therapeutics’ competitors have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Profitability

This table compares Rani Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Rani Therapeutics Competitors	-12,346.73%	-197.60%	-30.56%

Summary

Rani Therapeutics beats its competitors on 7 of the 13 factors compared.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.